Inovio Pharmaceuticals (NASDAQ:INO) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) to a sell rating in a report issued on Friday morning.

Several other equities analysts have also issued reports on the stock. Royal Bank of Canada cut their price objective on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a report on Wednesday. JMP Securities reissued a “market outperform” rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Finally, HC Wainwright reissued a “neutral” rating and set a $3.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $12.20.

Inovio Pharmaceuticals Stock Performance

Inovio Pharmaceuticals stock opened at $1.92 on Friday. The company has a 50 day moving average price of $2.04 and a 200-day moving average price of $3.71. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75. The company has a market capitalization of $50.11 million, a PE ratio of -0.91 and a beta of 0.92.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.18. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.03 million. On average, analysts forecast that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of INO. Alpine Global Management LLC purchased a new position in Inovio Pharmaceuticals in the fourth quarter worth $31,000. BNP Paribas Financial Markets lifted its stake in shares of Inovio Pharmaceuticals by 177.0% during the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 3,630 shares during the period. Bank of Montreal Can acquired a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth $43,000. Boothbay Fund Management LLC acquired a new stake in shares of Inovio Pharmaceuticals during the fourth quarter worth $44,000. Finally, Barclays PLC lifted its stake in shares of Inovio Pharmaceuticals by 15.0% during the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 5,111 shares during the period. 26.79% of the stock is owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.